Opthea Limited (ASX:OPT) is a public biotechnology company listed on the ASX and based in Melbourne Australia.
Opthea’s extensive intellectual property related to VEGF-C, VEGF-D and VEGFR-3 is held in its 100% owned subsidiary Vegenics Pty Ltd.
In addition to Opthea’s OPT-302 program for wet AMD, the company also has a number of non-core assets as a result of its historical research and development projects. These non-core programs are housed in a 100% owned subsidiary of Opthea.
A brief history of Opthea Limited
Circadian Technologies changed its name to Opthea Limited in December 2015. Coinciding with the name change, the company’s ASX code changed from CIR to OPT.
Circadian Technologies was founded by Leon Serry and was one of Australia’s earliest biotechnology companies. It listed on the Australian Stock Exchange in 1985.
Originally functioning as a commercial vehicle for outstanding, diverse biomedical research, the company successfully launched and spun out many of Australia's most prominent biotechnology companies including Axon Instruments, Optiscan Imaging and Antisense Therapeutics.
In 2008 Circadian modified its strategy to focus on the development of biologics-based therapies, in particular leveraging the broad intellectual property in respect of VEGF-C, VEGF-D and VEGFR-3, which is held within Opthea’s 100 percent-owned subsidiary, Vegenics Pty Ltd.